Vice Chancellor Donald F. Parsons Jr. has ordered Siga Technologies Inc. to share half of its profits from a smallpox drug with PharmAthene Inc.
In his 118-page opinion inPharmAthene v. Siga , Parsons ruled that Siga breached its obligation to negotiate in good faith on ST-246, an antiviral drug for use in case of a biological attack and, therefore, must share half of its profits with PharmAthene once the product reaches $40 million in sales.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
